IUGNF yields 1788.91% · MRK yields 2.76%● Live data
📍 IUGNF pulled ahead of the other in Year 1
Combined, IUGNF + MRK cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IUGNF + MRK for your $10,000?
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
Full IUGNF Calculator →Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Full MRK Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.